Vascular Solutions introduces ThrombiDisc topical hemostat in US

21 January 2014 (Last Updated January 21st, 2014 18:30)

Vascular Solutions has launched ThrombiDisc topical hemostat, a pad designed to control surface bleeding from vascular access sites and percutaneous catheters or tubes.

Vascular Solutions has launched ThrombiDisc topical hemostat, a thrombin-based pad designed to control surface bleeding from vascular access sites and percutaneous catheters or tubes.

It consists of a lyophilised bovine thrombin, a protein substance that gives the bandage its bleeding control properties, and silver chloride, which provides antimicrobial properties.

The 1in sterile pad is designed to use as an adjunct to manual compression. The pre-formed slit and 4mm diameter hole in the ThrombiDisc allow for placement around indwelling lines up to 12F.

"While other pads placed around indwelling lines merely absorb blood, ThrombiDisc addresses the bleeding problem with an active ingredient."

Vascular Solutions CEO Howard Root said effective control of bleeding around indwelling vascular access devices is a clinical imperative that ThrombiDisc was designed specifically to meet.

"While other pads placed around indwelling lines merely absorb blood, ThrombiDisc addresses the bleeding problem with an active ingredient," Root said. "In-vitro testing has demonstrated ThrombiDisc's ability to create a much quicker clot compared to the two most popular alternatives."

ThrombiDisc releases ionic silver in the presence of fluids such as blood and wound fluids from the silver chloride to prevent microorganisms commonly encountered in the clinical setting from colonising on the pad.

Ionic silver is an atom of silver that is missing one electron. It provides its antimicrobial property by altering protein structures and preventing bacterial cells from carrying out normal functions.

According to the company, the representative samples of ThrombiDisc killed at least 99.99% of seven common microbes known to cause catheter-related bloodstream infections (CRBSIs) after 24 hours of contact in in-vitro testing.

According to GlobalData estimates, the thrombin-based hemostats market in the US was valued at $243.9m in 2012 and is expected to grow at a CAGR of 6.3% to reach $374.5m by 2019.